Catalyst Will Try To Salvage Rare Disease Drug from Failed Phase III Trial
Executive Summary
Despite a Phase III study that found no statistically significant outcomes for its endpoints for Firdapse, Catalyst will seek FDA approval for treating a subgroup of patients who showed improvement